Clinical Programs


ALRN-6924 is a first-in-class, stabilized cell-permeating alpha-helical peptide that mimics the p53 tumor suppressor protein to disrupt p53’s interactions with its endogenous inhibitors, MDMX and MDM2.

Our clinical development program is focused on a Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-induced toxicities, and a Phase 2a clinical trial combining Aileron’s lead product candidate ALRN-6924 and Pfizer’s palbociclib (IBRANCE®), for the treatment of patients with MDM2-amplified cancers. Our first myelopreservation clinical trial is in small cell lung cancer patients treated with the chemotherapy topotecan.



Clinical Trials

ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of cancers and for the purpose of testing ALRN-6924 as a therapeutic agent that can protect cancer patients from chemotherapeutic toxicities (“Myelopreservation Trial”).  Preliminary clinical results have demonstrated a favorable safety profile and evidence of durable antitumor activity.

Our ongoing clinical trials of ALRN-6924 include:

  • Phase 1b/2 trial of ALRN-6924 as a myelopreservation drug in small cell lung cancer (SCLC) patients treated with topotecan
  • Phase 2a trial in combination with Palbociclib for MDM2 amplified or MDM2/CDK4 co-amplified solid tumors

Past clinical trials of ALRN-6924:

  • Phase 1 trial for the treatment of acute myeloid leukemia (AML), and advanced myelodysplastic syndrome (MDS), as a monotherapy
  • Phase 1b trial for the treatment of AML/MDS in combination with cytosine arabinoside (Ara-C)
  • Phase 2a trial for the treatment of peripheral T-cell lymphoma (PTCL)

For more information, access our ongoing trial updates at